New drug cocktail aims to tackle rare lymphoma
NCT ID NCT06504940
First seen Mar 01, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This study tests a new drug called orelabrutinib combined with chemotherapy for people newly diagnosed with marginal zone lymphoma, a rare blood cancer. Researchers want to see if the combination helps shrink tumors and keeps the cancer from coming back. The trial includes two groups: younger patients getting orelabrutinib with bendamustine and rituximab, and older or frailer patients getting orelabrutinib with obinutuzumab. All participants who respond well will continue on orelabrutinib alone as maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital ，Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orelabrutinib combined with bendamustine and rituximab or obinutuzumab
What this could lead to
If successful, this could offer a more effective first-line treatment for marginal zone lymphoma, potentially leading to longer remission and better disease control.
What could go wrong
This is an early-phase trial with only 69 participants, so results may not apply to all patients. The drug combination can cause side effects like low blood counts and infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.